The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?

scientific article published on 25 May 2016

The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals? is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2016PLoSO..1156213S
P356DOI10.1371/JOURNAL.PONE.0156213
P932PMC publication ID4880220
P698PubMed publication ID27224423

P50authorEmma S. McBrydeQ39990382
Jack StoneQ60164968
Peter VickermanQ61912869
Margaret E HellardQ85903750
Matthew HickmanQ37828999
Heidi E DrummerQ38323304
P2093author name stringNatasha K Martin
Nick Scott
P2860cites workHepatitis C virus therapeutic development: in pursuit of "perfectovir".Q38374284
Hepatitis C: the next 25yearsQ39156863
Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settingsQ39559418
Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.Q39866377
People who inject drugs in prison: HIV prevalence, transmission and preventionQ41458000
Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trialQ42225127
The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.Q42602432
A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in AustraliaQ43419623
Estimating the prevalence of ex-injecting drug use in the population.Q43428423
Cost-effectiveness analysis of a hypothetical hepatitis C vaccine compared to antiviral therapyQ43517228
Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health actionQ44412085
Disparity in market prices for hepatitis C virus direct-acting drugsQ45340234
Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populationsQ45363548
Hepatitis B vaccine uptake among injecting drug users in England 1998 to 2004: is the prison vaccination programme driving recent improvements?Q47573169
The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic.Q52295844
New Expensive Treatments for Hepatitis C InfectionQ57255675
Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in CanadaQ57695969
Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utilityQ57701087
Hepatitis B vaccination in prisons: the Catalonian experienceQ72779415
Look behind bars for key to control of STDsQ74082675
Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviewsQ24630669
Global epidemiology and genotype distribution of the hepatitis C virus infectionQ27001240
Hepatitis C Infection Among Injecting Drug Users in England and Wales (1992-2006): There and Back Again?Q27488973
Global epidemiology of hepatitis C virus infectionQ27860799
A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humansQ28488268
Vaccination of chimpanzees against infection by the hepatitis C virusQ29615899
Potential impact of vaccination on the hepatitis C virus epidemic in injection drug usersQ33824723
Dancing with chemical formulae of antivirals: A panoramic view (Part 2).Q34038340
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.Q34320498
Pertussis circulation has increased T-cell immunity during childhood more than a second acellular booster vaccination in Dutch children 9 years of age.Q34364307
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regressionQ34787367
Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.Q35109126
HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact.Q35535844
Adherence to hepatitis B virus vaccination at syringe exchange sitesQ36274505
Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studiesQ36346436
Economic evaluation of delivering hepatitis B vaccine to injection drug usersQ36789998
Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapyQ37042425
Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and placeQ37306146
Interventions to reduce HIV transmission related to injecting drug use in prisonQ37354455
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antiviralsQ37601315
Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodiesQ38234934
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue5
P407language of work or nameEnglishQ1860
P304page(s)e0156213
P577publication date2016-05-25
P1433published inPLOS OneQ564954
P1476titleThe Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?
P478volume11

Reverse relations

cites work (P2860)
Q61813267A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection
Q61958644Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
Q59351582Approaches, Progress, and Challenges to Hepatitis C Vaccine Development
Q39333862Designing an HCV vaccine: a unique convergence of prevention and therapy?
Q57161290HIV, HCV and HBV: A Review of Parallels and Differences
Q39238761Hepatitis C treatment as prevention: evidence, feasibility, and challenges
Q89725315Hepatitis C vaccine: 10 good reasons for continuing
Q57162382Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges
Q97418726Hepatitis C virus vaccine design: focus on the humoral immune response
Q38635796Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era.
Q59350606Mathematical modeling of hepatitis c virus (HCV) prevention among people who inject drugs: A review of the literature and insights for elimination strategies
Q92951971Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago
Q52315227Opioids, Hepatitis C Virus Infection, and the Missing Vaccine.
Q52597010Research gaps in viral hepatitis.
Q45324462The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine
Q63246174Toward DNA-Based T-Cell Mediated Vaccines to Target HIV-1 and Hepatitis C Virus: Approaches to Elicit Localized Immunity for Protection

Search more.